Similarly, another meta-analysis performed by Montes et al. in 429 Caucasian patients diagnosed with RA and receiving TNFi therapy found no association between the FCGR3A rs396991 polymorphism and response to BTs (p = 0.5; OR = 1.11; 95% CI = 0.8–1.5; I2 = 62) [4]. This evidence concerns the gene FCGR3A and rheumatoid arthritis.